Amneal Pharmaceuticals Statistics
Total Valuation
AMRX has a market cap or net worth of $6.68 billion. The enterprise value is $9.34 billion.
| Market Cap | 6.68B |
| Enterprise Value | 9.34B |
Important Dates
The next confirmed earnings date is Tuesday, November 3, 2026, before market open.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AMRX has 348.30 million shares outstanding. The number of shares has increased by 3.48% in one year.
| Current Share Class | 348.30M |
| Shares Outstanding | 348.30M |
| Shares Change (YoY) | +3.48% |
| Shares Change (QoQ) | -0.25% |
| Owned by Insiders (%) | 38.19% |
| Owned by Institutions (%) | 48.40% |
| Float | 215.21M |
Valuation Ratios
The trailing PE ratio is 39.89 and the forward PE ratio is 19.12. AMRX's PEG ratio is 2.12.
| PE Ratio | 39.89 |
| Forward PE | 19.12 |
| PS Ratio | 2.14 |
| Forward PS | 2.06 |
| PB Ratio | 185.46 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 80.38 |
| P/OCF Ratio | 33.27 |
| PEG Ratio | 2.12 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.55, with an EV/FCF ratio of 112.39.
| EV / Earnings | 59.36 |
| EV / Sales | 3.00 |
| EV / EBITDA | 13.55 |
| EV / EBIT | 18.86 |
| EV / FCF | 112.39 |
Financial Position
The company has a current ratio of 2.20, with a Debt / Equity ratio of 23.87.
| Current Ratio | 2.20 |
| Quick Ratio | 1.37 |
| Debt / Equity | 23.87 |
| Debt / EBITDA | 3.94 |
| Debt / FCF | 33.59 |
| Interest Coverage | 2.18 |
Financial Efficiency
Return on equity (ROE) is 613.02% and return on invested capital (ROIC) is 18.64%.
| Return on Equity (ROE) | 613.02% |
| Return on Assets (ROA) | 8.60% |
| Return on Invested Capital (ROIC) | 18.64% |
| Return on Capital Employed (ROCE) | 17.11% |
| Weighted Average Cost of Capital (WACC) | 9.62% |
| Revenue Per Employee | $358,339 |
| Profits Per Employee | $18,088 |
| Employee Count | 8,700 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 2.92 |
Taxes
| Income Tax | -14.14M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +96.12% in the last 52 weeks. The beta is 1.22, so AMRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.22 |
| 52-Week Price Change | +96.12% |
| 50-Day Moving Average | 18.56 |
| 200-Day Moving Average | 15.36 |
| Relative Strength Index (RSI) | 48.96 |
| Average Volume (20 Days) | 3,028,707 |
Short Selling Information
The latest short interest is 11.28 million, so 3.24% of the outstanding shares have been sold short.
| Short Interest | 11.28M |
| Short Previous Month | 11.29M |
| Short % of Shares Out | 3.24% |
| Short % of Float | 5.24% |
| Short Ratio (days to cover) | 4.13 |
Income Statement
In the last 12 months, AMRX had revenue of $3.12 billion and earned $157.36 million in profits. Earnings per share was $0.48.
| Revenue | 3.12B |
| Gross Profit | 1.24B |
| Operating Income | 495.15M |
| Pretax Income | 201.18M |
| Net Income | 157.36M |
| EBITDA | 689.44M |
| EBIT | 495.15M |
| Earnings Per Share (EPS) | $0.48 |
Balance Sheet
The company has $131.41 million in cash and $2.79 billion in debt, with a net cash position of -$2.66 billion or -$7.64 per share.
| Cash & Cash Equivalents | 131.41M |
| Total Debt | 2.79B |
| Net Cash | -2.66B |
| Net Cash Per Share | -$7.64 |
| Equity (Book Value) | 116.98M |
| Book Value Per Share | 0.10 |
| Working Capital | 1.06B |
Cash Flow
In the last 12 months, operating cash flow was $200.78 million and capital expenditures -$117.67 million, giving a free cash flow of $83.11 million.
| Operating Cash Flow | 200.78M |
| Capital Expenditures | -117.67M |
| Depreciation & Amortization | 194.29M |
| Net Borrowing | 228.33M |
| Free Cash Flow | 83.11M |
| FCF Per Share | $0.24 |
Margins
Gross margin is 39.81%, with operating and profit margins of 15.88% and 5.05%.
| Gross Margin | 39.81% |
| Operating Margin | 15.88% |
| Pretax Margin | 6.45% |
| Profit Margin | 5.05% |
| EBITDA Margin | 22.11% |
| EBIT Margin | 15.88% |
| FCF Margin | 2.67% |
Dividends & Yields
AMRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.48% |
| Shareholder Yield | -3.48% |
| Earnings Yield | 2.36% |
| FCF Yield | 1.24% |
Analyst Forecast
The average price target for AMRX is $22.71, which is 18.41% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $22.71 |
| Price Target Difference | 18.41% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 8.06% |
| EPS Growth Forecast (3Y) | 20.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AMRX has an Altman Z-Score of 2.06 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.06 |
| Piotroski F-Score | 7 |